University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Location status: Recruiting
Location contact
Nicole Ochsenbein, Prof. Dr. med
CONTACT
Verena Bossung, PD Dr. med
CONTACT
NCT Number: NCT07587632
As of today, around 25% of all vaginal births happen after induction of labor (IOL). The internal guidelines of the University Hospital Zurich currently recommend pregnant women with a non-insulin dependent gestational diabetes an IOL around term. One possibility to prevent an IOL and increase the chance for a spontaneous onset of birth is a ripening of the cervix by alternative methods in an outpatient setting. The primary objective of this study is to evaluate the effect of natural cervical ripening methods on the time interval between 37 weeks (beginning of the intervention) and the onset of spontaneous labor.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Zurich, Canton of Zurich, 8091, Switzerland
Location status: Recruiting
Nicole Ochsenbein, Prof. Dr. med
CONTACT
Verena Bossung, PD Dr. med
CONTACT
Approximately 25% of vaginal births currently occur following induction of labor (IOL). At the University Hospital Zurich, internal guidelines recommend IOL at 40 weeks of gestation for women with non-insulin-dependent, diet-controlled gestational diabetes. However, IOL may be associated with side effects and a less positive birth experience. Alternative, natural methods for cervical ripening in an outpatient setting may help promote spontaneous labor onset and reduce the need for medical induction.
This investigator-initiated, mono-centric, prospective, randomized controlled trial aims to evaluate the effectiveness, safety, and feasibility of natural cervical ripening methods, specifically nipple stimulation (breast massage/colostrum harvesting) and membrane sweeping. The primary objective is to assess whether these interventions shorten the time from 37 weeks of gestation (start of intervention) to the onset of spontaneous labor.
The primary endpoint is the time interval between 37 weeks' gestation and spontaneous onset of labor. Secondary endpoints include the rate of spontaneous labor before planned IOL, oxytocin use during childbirth, use of pharmacological induction agents, duration of hospitalization, postpartum hemorrhage (>500 ml), mode of birth, patient satisfaction with the intervention/induction and birth experience, and neonatal outcomes.
The study includes 74 pregnant women aged ≥18 years with singleton pregnancies, diet-controlled gestational diabetes, planned vaginal birth, and scheduled IOL at 40 weeks, who can communicate in German or English and have provided informed consent. Key exclusion criteria include multiple gestation, fetal growth abnormalities, insulin-dependent diabetes, planned cesarean section, onset of labor prior to enrollment, or inability to comply with study procedures.
Participants are randomized to either an intervention group or a control group. The intervention group receives membrane sweeping twice weekly by medical personnel from 37 weeks, breast massage/nipple stimulation performed by the participant for 60 minutes on three days per week, and standard colostrum harvesting beginning at 36 weeks. The control group receives standard care only, consisting of colostrum harvesting twice daily from 36 weeks, which is already routine practice at the institution.
Data collection includes questionnaires during the intervention phase (assessing experience, compliance, and side effects) and after delivery (assessing satisfaction with the intervention or IOL and overall birth experience). Recruitment takes place during routine prenatal visits or at the lactation outpatient clinic of the University Hospital Zurich. Following informed consent and confirmation of eligibility, participants are enrolled and randomized.
The anticipated benefits include increased spontaneous onset of labor, reduced need for IOL and oxytocin, decreased postpartum hemorrhage, and improved maternal satisfaction with the birth experience. Given the natural nature of the interventions, risks are considered low, primarily mild vaginal bleeding or discomfort during membrane sweeping.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Study intervention:
Time frame: Between 37/0 weeks of gestation until the onset of labor
Contact information is provided by the study sponsor or research team.
Nicole Ochsenbein, Prof. Dr. med
CONTACT
Verena Bossung, PD Dr. med.
CONTACT
University of Zurich
Other
Acronym: Cervinat
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470320
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oxford, United Kingdom
View Trial DetailsNCT07446205
Adnexal Diseases, Diabetes Mellitus
Honolulu, Hawaii, United States
View Trial DetailsNCT07565727
Cardiometabolic Diseases, Diabetes Mellitus
Knoxville, Tennessee, United States
View Trial DetailsNCT07459907
Diabetes Mellitus, Diabetes, Gestational
Graz, Austria
View Trial Details